PropertyValue
?:abstract
  • Remdesivir is presently been considered as \'molecule of hope\' to curb the menace of COVID19. Non-availability of any USFDA approved drug has led to several attempt of drug-repurposing and development of new therapeutic molecules. However, Remdesivir has been found to be effective against a broad range of virus including SARS, MERS and COVID 19 through in-vitro studies. Several clinical research attempt are presently being conducted showing promising result yet not conclusive. This review summarized all such clinical trials to critically appraise the usage of Remdesivir against COVID 19 along with the publications related to the results of the clinical studies. The present regulatory aspect i. e. Emergency Use Authorization (EYA) and information of molecule and plausible mechanism is also dealt.
is ?:annotates of
?:creator
?:journal
  • Drug_res._(Stuttg.,_2013,_Internet)
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment
?:type
?:who_covidence_id
  • #894442
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/cvslak4x>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/cvslak4x>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all